Commercialization· September 10, 2026 · 21 min read
ChinaMedGlobal: Checking Access Assumptions in a Licensed Drug Data Room
By Ran Chen#Market Access#Coverage Access#Payer Policy
Topic
M&A
Mergers and acquisitions, licensing deals, partnership terms, and alliance structures that reshape therapeutic-area competition and pipeline strategy.
Deals· August 8, 2026 · 15 min read
Servier's $2.5B Day One deal: tovorafenib (Ojemda) & first EU JCA completion
By Ran Chen#Servier#Day One#Tovorafenib
Deals· August 6, 2026 · 13 min read
Gilead's $7.8B Arcellx Acquisition: Anito-Cel Deal Anatomy
By Ran Chen#Gilead Sciences#Arcellx#anito-cel
Deals· August 5, 2026 · 19 min read
Lilly's $3.8B AtaiBeckley deal: big pharma validates psychedelics for TRD
By Ran Chen#M&A#Eli Lilly#Psychedelic Therapy
Deals· August 3, 2026 · 15 min read
Neurocrine's $2.9 Billion Soleno Acquisition: Vykat XR and the Prader-Willi Franchise
By Ran Chen#M&A#Rare Disease#Orange Book
Deals· August 2, 2026 · 25 min read
Angelini Pharma's $4.1B Catalyst Acquisition: Rare Disease Deal Anatomy
By Ran Chen#M&A#Rare Disease#Orange Book
Deals· August 1, 2026 · 20 min read
Gilead's $5B Tubulis Buyout: Deal Anatomy & NaPi2b ADC Platform
By Ran Chen#M&A#ADC#FDA Approval
Deals· July 31, 2026 · 19 min read
argenx's $2.2B Forte Biosciences Deal: FB102 Anti-CD122 & Vyvgart Synergy
By Ran Chen#M&A#Immunology#Clinical Evidence
Deals· July 30, 2026 · 21 min read
Biogen's $5.6B Apellis Acquisition: Syfovre & Empaveli Q2 2026 Financial Deep Dive
By Ran Chen#M&A#Commercial Strategy#Ophthalmology
Pipeline· July 28, 2026 · 25 min read